TABLE 3.
Evaluation of delayed MTX elimination, acute kidney injury, and hospital length of stay in lymphoma patients receiving HDMTX with or without concomitant levetiracetam
| Levetiracetam N = 349 administrations | No levetiracetam N = 1614 administrations | OR (95% CI) | p-Value | |
|---|---|---|---|---|
| MTX level at 48 h, μmol/L, median (IQR) | 0.31 (0.18, 0.59) | 0.37 (0.18, 0.79) | NA | 0.54 |
| Patients with 48 h MTX level >1 μmol/L, no. (%) | 49 (14.0%) | 261 (16.2%) | 0.80 (0.47–1.34) | 0.39 |
| Patients with AKI, no. (%) | ||||
| No AKI | 323 (85.4) | 1326 (83.0) | 0.83 (0.52–1.33) | 0.28 |
| Stage I | 38 (10.1) | 204 (12.8) | ||
| Stage II | 12 (3.2) | 54 (3.4) | ||
| Stage III | 5 (1.3) | 13 (0.8) | ||
| LOS, days, median (IQR)a | 4.2 (3.9, 6.1) | 4.1 (3.8, 5.8) | NA | 0.039 |
Abbreviations: AKI, acute kidney injury; CI, confidence interval IQR, interquartile range; LOS, length of stay; MTX, methotrexate.
a
Excluding patients who received multiple HDMTX administrations in a single hospitalization.